InvestorsHub Logo
Followers 0
Posts 62
Boards Moderated 0
Alias Born 09/16/2012

Re: Falconoffury post# 4801

Saturday, 08/17/2013 11:31:36 PM

Saturday, August 17, 2013 11:31:36 PM

Post# of 6805
I think the chances of rejection (ODD) are high because the chronic neuropathic pain in cancer patient market is clearly larger than 200,000. According Jason Napodano, "a deal is contingent upon ODD. With ODD + partner, $1.50 doable". I'm wondering if investors will take the chance. What do you think?